Resverlogix Corp. (TSE:RVX – Get Free Report) hit a new 52-week low on Monday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 1525 shares changing hands. The stock had previously closed at C$0.05.
Resverlogix Stock Down 20.0 %
The company has a quick ratio of 0.04, a current ratio of 0.13 and a debt-to-equity ratio of -10.95. The company’s fifty day moving average price is C$0.05 and its 200-day moving average price is C$0.06. The stock has a market capitalization of C$7.92 million, a PE ratio of -1.98 and a beta of 0.71.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Transportation Stocks Investing
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
